Fortress Biotech Stock Revenue Per Share

FBIO Stock  USD 1.97  0.06  2.96%   
Fortress Biotech fundamentals help investors to digest information that contributes to Fortress Biotech's financial success or failures. It also enables traders to predict the movement of Fortress Stock. The fundamental analysis module provides a way to measure Fortress Biotech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Fortress Biotech stock.
Last ReportedProjected for Next Year
Revenue Per Share 11.98  16.95 
As of the 13th of January 2025, Revenue Per Share is likely to grow to 16.95.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Fortress Biotech Company Revenue Per Share Analysis

Fortress Biotech's Revenue per Share is a ratio of total revenue earned per one share of common stock over a single fiscal year. It is calculated by dividing sales revenue earned over 12 months by the average number of outstanding shares. Revenue used in the calculation of this ratio is typically recorded when cash or cash equivalents are exchanged for services or goods.

Current Fortress Biotech Revenue Per Share

    
  16.95  
Most of Fortress Biotech's fundamental indicators, such as Revenue Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Fortress Biotech is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Fortress Revenue Per Share Driver Correlations

Understanding the fundamental principles of building solid financial models for Fortress Biotech is extremely important. It helps to project a fair market value of Fortress Stock properly, considering its historical fundamentals such as Revenue Per Share. Since Fortress Biotech's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Fortress Biotech's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Fortress Biotech's interrelated accounts and indicators.
0.740.730.810.240.70.58-0.61-0.730.610.980.630.570.90.810.480.120.760.460.550.44-0.63
0.740.870.950.40.69-0.03-0.08-0.820.640.680.730.380.890.830.76-0.030.780.660.03-0.09-0.57
0.730.870.950.460.72-0.030.04-0.860.650.640.70.380.860.860.76-0.120.870.660.04-0.15-0.61
0.810.950.950.280.810.06-0.11-0.910.630.730.80.540.950.940.71-0.110.880.580.12-0.06-0.73
0.240.40.460.28-0.09-0.250.16-0.110.520.17-0.1-0.440.190.110.690.140.220.85-0.3-0.060.28
0.70.690.720.81-0.090.22-0.12-0.950.470.690.860.660.840.890.51-0.30.930.270.28-0.12-0.97
0.58-0.03-0.030.06-0.250.22-0.85-0.110.180.660.10.580.270.22-0.190.230.13-0.170.750.71-0.27
-0.61-0.080.04-0.110.16-0.12-0.850.03-0.02-0.690.02-0.37-0.3-0.20.19-0.16-0.040.09-0.76-0.920.16
-0.73-0.82-0.86-0.91-0.11-0.95-0.110.03-0.57-0.68-0.85-0.61-0.87-0.94-0.640.22-0.96-0.42-0.090.210.89
0.610.640.650.630.520.470.18-0.02-0.570.550.490.350.660.60.650.270.590.660.02-0.03-0.36
0.980.680.640.730.170.690.66-0.69-0.680.550.570.570.860.750.430.040.710.410.640.51-0.63
0.630.730.70.8-0.10.860.10.02-0.850.490.570.60.830.770.440.030.790.250.22-0.24-0.8
0.570.380.380.54-0.440.660.58-0.37-0.610.350.570.60.580.710.11-0.050.49-0.150.330.1-0.74
0.90.890.860.950.190.840.27-0.3-0.870.660.860.830.580.890.61-0.060.860.510.390.14-0.77
0.810.830.860.940.110.890.22-0.2-0.940.60.750.770.710.890.61-0.170.90.410.14-0.03-0.85
0.480.760.760.710.690.51-0.190.19-0.640.650.430.440.110.610.61-0.210.650.9-0.25-0.31-0.35
0.12-0.03-0.12-0.110.14-0.30.23-0.160.220.270.040.03-0.05-0.06-0.17-0.21-0.240.050.020.170.38
0.760.780.870.880.220.930.13-0.04-0.960.590.710.790.490.860.90.65-0.240.470.17-0.15-0.86
0.460.660.660.580.850.27-0.170.09-0.420.660.410.25-0.150.510.410.90.050.47-0.16-0.09-0.07
0.550.030.040.12-0.30.280.75-0.76-0.090.020.640.220.330.390.14-0.250.020.17-0.160.75-0.32
0.44-0.09-0.15-0.06-0.06-0.120.71-0.920.21-0.030.51-0.240.10.14-0.03-0.310.17-0.15-0.090.750.08
-0.63-0.57-0.61-0.730.28-0.97-0.270.160.89-0.36-0.63-0.8-0.74-0.77-0.85-0.350.38-0.86-0.07-0.320.08
Click cells to compare fundamentals

Fortress Revenue Per Share Historical Pattern

Today, most investors in Fortress Biotech Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Fortress Biotech's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's revenue per share growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Fortress Biotech revenue per share as a starting point in their analysis.
   Fortress Biotech Revenue Per Share   
       Timeline  
Revenue per share does not take into account any of company expenses and is helpful only when comparing relative sale figures within a given industry.
Competition

Fortress Common Stock Shares Outstanding

Common Stock Shares Outstanding

9.79 Million

At this time, Fortress Biotech's Common Stock Shares Outstanding is very stable compared to the past year.

Fortress Revenue Per Share Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Fortress Biotech's direct or indirect competition against its Revenue Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Fortress Biotech could also be used in its relative valuation, which is a method of valuing Fortress Biotech by comparing valuation metrics of similar companies.
6.150.013.5616.66100%
Fortress Biotech is currently under evaluation in revenue per share category among its peers.

Fortress Biotech Current Valuation Drivers

We derive many important indicators used in calculating different scores of Fortress Biotech from analyzing Fortress Biotech's financial statements. These drivers represent accounts that assess Fortress Biotech's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Fortress Biotech's important valuation drivers and their relationship over time.
202020212022202320242025 (projected)
Market Cap228.3M204.3M58.7M24.4M22.0M20.9M
Enterprise Value84.0M(26.5M)7.7M32.1M36.9M53.6M

Fortress Biotech ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Fortress Biotech's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Fortress Biotech's managers, analysts, and investors.
56.8%
Environmental
64.6%
Governance
Social

Fortress Fundamentals

Return On Equity-17.4
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-310%500%1,000%1,500%2,000%
Return On Asset-0.36
Profit Margin(0.49) %
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-100%-80%-60%-40%-20%
Operating Margin(1.69) %
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-100%-80%-60%-40%-20%
Current Valuation68.72 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-100%-50%0%50%
Shares Outstanding27.56 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-50%0%50%100%150%200%
Shares Owned By Insiders21.20 %
Shares Owned By Institutions14.46 %
Number Of Shares Shorted3.4 M
Price To Earning(2.92) X
Price To Book2.65 X
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-80%-60%-40%-20%
Price To Sales0.68 X
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-100%-80%-60%-40%-20%
Revenue84.51 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31
Gross Profit(85.66 M)
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31
EBITDA(133.64 M)
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31500%1,000%1,500%2,000%
Net Income(60.64 M)
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31500%1,000%1,500%2,000%
Cash And Equivalents208.35 M
Cash Per Share1.92 X
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31500%1,000%1,500%
Total Debt88.59 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-315,000%10,000%15,000%
Debt To Equity1.24 %
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-3120,000%40,000%60,000%80,000%100,000%
Current Ratio2.43 X
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-50%0%50%100%150%
Book Value Per Share0.79 X
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-310%500%1,000%1,500%
Cash Flow From Operations(128.22 M)
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31500%1,000%1,500%2,000%2,500%3,000%
Short Ratio4.57 X
Earnings Per Share(27.73) X
Price To Earnings To Growth(0.10) X
Target Price14.0
Number Of Employees186
Beta1.75
Market Capitalization46.86 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-50%0%50%100%
Total Asset167.53 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-315,000%10,000%15,000%20,000%
Retained Earnings(694.87 M)
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31200%400%600%800%1,000%1,200%
Working Capital32.11 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31
Current Asset99.94 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31200%400%600%800%1,000%1,200%1,400%
Current Liabilities10.58 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-310%200%400%600%800%1,000%
Net Asset167.53 M

About Fortress Biotech Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Fortress Biotech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Fortress Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Fortress Biotech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Pair Trading with Fortress Biotech

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Fortress Biotech position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Fortress Biotech will appreciate offsetting losses from the drop in the long position's value.

Moving against Fortress Stock

  0.46DNLI Denali TherapeuticsPairCorr
  0.43JNJ Johnson Johnson Earnings Call Next WeekPairCorr
  0.37UPC Universe PharmaceuticalsPairCorr
The ability to find closely correlated positions to Fortress Biotech could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Fortress Biotech when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Fortress Biotech - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Fortress Biotech to buy it.
The correlation of Fortress Biotech is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Fortress Biotech moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Fortress Biotech moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Fortress Biotech can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Fortress Biotech offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Fortress Biotech's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Fortress Biotech Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Fortress Biotech Stock:
Check out Fortress Biotech Piotroski F Score and Fortress Biotech Altman Z Score analysis.
To learn how to invest in Fortress Stock, please use our How to Invest in Fortress Biotech guide.
You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Fortress Biotech. If investors know Fortress will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Fortress Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(27.73)
Revenue Per Share
6.15
Quarterly Revenue Growth
(0.14)
Return On Assets
(0.36)
Return On Equity
(17.40)
The market value of Fortress Biotech is measured differently than its book value, which is the value of Fortress that is recorded on the company's balance sheet. Investors also form their own opinion of Fortress Biotech's value that differs from its market value or its book value, called intrinsic value, which is Fortress Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fortress Biotech's market value can be influenced by many factors that don't directly affect Fortress Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Fortress Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Fortress Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fortress Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.